Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Ultragenyx Pharmaceutical’s Earnings Outlook
Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Ultragenyx Pharmaceutical will report an earnings per share (EPS) of $-1.76.
Credit Suisse Upgrades Ultragenyx Pharmaceutical to Outperform, Raises Price Target to $105
Credit Suisse analyst Martin Auster upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Neutral to Outperform and raises the price target from $99 to $105.
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $118
Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $120 to $118.
JP Morgan Upgrades Ultragenyx Pharmaceutical to Overweight, Announces $132 Price Target
JP Morgan analyst Cory Kasimov upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Neutral to Overweight and announces $132 price target.
Ultragenyx Pharmaceutical: Q4 Earnings Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell
• Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.